Mr. Joe Todisco is Chief Executive Officer of CorMedix and a member of the Board of Directors. Prior to joining CorMedix, he spent eleven years in various roles at Amneal Pharmaceuticals, most recently as Chief Commercial Officer of Amneal Specialty, as well as Senior Vice President Corporate Development & International Operations. He was also co-founder and formerly chief executive of Gemini Laboratories LLC, a specialty pharmaceutical company that was subsequently acquired by Amneal. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy Pharmaceutical’s North American Commercial Strategy and Business Development, and prior to Ranbaxy, held various leadership roles with Par Pharmaceuticals. Joe holds a bachelor’s degree in Economics from Georgetown University and an M.B.A. from Fordham Graduate School of Business.
Matt David was appointed Executive Vice President and Chief Financial Officer in May 2020 and also served as CorMedix’s interim CEO from October 2021 to May 2022. He leads the company’s finance and investor relations activities. Prior to joining CorMedix, Dr. David was Head of Strategy at Ovid Therapeutics and spent the majority of his career in healthcare investment banking roles where he advised life sciences companies on a broad range of financing and strategic transactions. Earlier in his career, Dr. David spent time as a research analyst covering the pharma sector. Dr. David received his M.D. from NYU School of Medicine and his undergraduate degree from Dartmouth College.
Phoebe Mounts was appointed Executive Vice President and General Counsel in May 2019. She leads the company’s legal, compliance and regulatory affairs activities. Prior to joining CorMedix, Dr. Mounts was a partner at the law firm Morgan Lewis and Bockius LLP where since 2013 she advised the company with respect to its U.S. Food and Drug Administration (FDA) regulatory strategies for DefenCath™ and taurolidine. Dr. Mounts is a graduate of Georgetown University Law Center, prior to which she was on the faculty of the Johns Hopkins University School of Public Health for 16 years, specializing in molecular biology and infectious disease. She received her Ph.D. in molecular biology from the University of Edinburgh in Scotland.
Liz Masson Hurlburt serves as our Executive Vice President of Clinical & Medical Affairs. Prior to that, she held several progressive management roles in clinical operations, most recently at Gemphire Therapeutics, as Vice President, Clinical Operations. Responsible for strategic and clinical development activities, Liz has a passion for growing and developing highly engaged teams and assuring the highest standards for medical affairs and clinical development execution. Liz received her B.A. in Leadership and Organizational Management from Bay Path College and a Master’s in Management and Leadership from Western Governors University.
Erin Mistry is EVP and Chief Commercial Officer, appointed in January 2023. She served as SVP Payer Strategy, Government Affairs and Trade from 2020 to 2022. She leads the company’s commercial strategy and execution. Erin brings over 15 years of industry experience at the executive level from consulting to in-house executive management. Prior to joining CorMedix, Erin was Vice President of Market Access at Intarcia Therapeutics responsible for pricing, coverage, access, Real world evidence (RWE) and channel strategy for a competitive product in Type 2 Diabetes. Erin was also Senior Managing Director at Syneos Health where she was responsible for the global P&L of the Value Access Practice. In this capacity, Erin consulted on commercial strategy and market access with emerging, mid, and large biopharma across a broad range of therapeutic categories. Erin holds an undergraduate and Masters degree in Biomechanical Engineering from North Carolina State University.
